• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可预测一致性先验有效样本量。

Predictively consistent prior effective sample sizes.

机构信息

Novartis Pharma AG, Basel, Switzerland.

Sheffield University, Sheffield, UK.

出版信息

Biometrics. 2020 Jun;76(2):578-587. doi: 10.1111/biom.13252. Epub 2020 Apr 6.

DOI:10.1111/biom.13252
PMID:32142163
Abstract

Determining the sample size of an experiment can be challenging, even more so when incorporating external information via a prior distribution. Such information is increasingly used to reduce the size of the control group in randomized clinical trials. Knowing the amount of prior information, expressed as an equivalent prior effective sample size (ESS), clearly facilitates trial designs. Various methods to obtain a prior's ESS have been proposed recently. They have been justified by the fact that they give the standard ESS for one-parameter exponential families. However, despite being based on similar information-based metrics, they may lead to surprisingly different ESS for nonconjugate settings, which complicates many designs with prior information. We show that current methods fail a basic predictive consistency criterion, which requires the expected posterior-predictive ESS for a sample of size N to be the sum of the prior ESS and N. The expected local-information-ratio ESS is introduced and shown to be predictively consistent. It corrects the ESS of current methods, as shown for normally distributed data with a heavy-tailed Student-t prior and exponential data with a generalized Gamma prior. Finally, two applications are discussed: the prior ESS for the control group derived from historical data and the posterior ESS for hierarchical subgroup analyses.

摘要

确定实验的样本量可能具有挑战性,尤其是在通过先验分布纳入外部信息时。这种信息越来越多地用于减少随机临床试验中的对照组规模。了解先验信息的数量,以等效先验有效样本量 (ESS) 表示,显然有助于试验设计。最近已经提出了各种获取先验 ESS 的方法。它们的合理性在于它们为单参数指数族提供了标准的 ESS。然而,尽管基于相似的基于信息的指标,但它们可能会导致非共轭环境下令人惊讶的不同 ESS,这使得许多具有先验信息的设计变得复杂。我们表明,当前的方法未能通过基本的预测一致性标准,该标准要求大小为 N 的样本的后验预测 ESS 是先验 ESS 和 N 的总和。引入了期望局部信息比 ESS,并证明其具有预测一致性。它纠正了当前方法的 ESS,如具有重尾学生 t 先验的正态分布数据和具有广义伽马先验的指数数据所示。最后,讨论了两个应用:从历史数据中得出的对照组的先验 ESS 和分层子组分析的后验 ESS。

相似文献

1
Predictively consistent prior effective sample sizes.可预测一致性先验有效样本量。
Biometrics. 2020 Jun;76(2):578-587. doi: 10.1111/biom.13252. Epub 2020 Apr 6.
2
Robust meta-analytic-predictive priors in clinical trials with historical control information.具有历史对照信息的临床试验中的稳健元分析预测先验。
Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29.
3
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.贝叶斯半参数荟萃分析-预测先验在临床试验中对历史对照数据的借鉴。
Stat Med. 2021 Jun 30;40(14):3385-3399. doi: 10.1002/sim.8970. Epub 2021 Apr 13.
4
Quantification of prior impact in terms of effective current sample size.根据有效当前样本量来量化先前的影响。
Biometrics. 2020 Mar;76(1):326-336. doi: 10.1111/biom.13124. Epub 2019 Sep 13.
5
Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.临床试验样本量计算的荟萃分析预测方法分析。
Res Synth Methods. 2023 May;14(3):396-413. doi: 10.1002/jrsm.1618. Epub 2023 Jan 14.
6
Summarizing historical information on controls in clinical trials.总结临床试验中对照的历史信息。
Clin Trials. 2010 Feb;7(1):5-18. doi: 10.1177/1740774509356002.
7
Sample size re-estimation incorporating prior information on a nuisance parameter.纳入关于干扰参数的先验信息的样本量重新估计。
Pharm Stat. 2018 Mar;17(2):126-143. doi: 10.1002/pst.1837. Epub 2017 Nov 27.
8
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.随机对照试验中的亚组分析:量化假阳性和假阴性风险
Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330.
9
Utilizing shared internal control arms and historical information in small-sized platform clinical trials.在小型平台临床试验中利用共享的内部对照臂和历史信息。
J Biopharm Stat. 2019;29(5):845-859. doi: 10.1080/10543406.2019.1657132. Epub 2019 Aug 28.
10
Bayesian Phase II optimization for time-to-event data based on historical information.基于历史信息的贝叶斯Ⅱ期优化时间至事件数据。
Stat Methods Med Res. 2019 Apr;28(4):1272-1289. doi: 10.1177/0962280217747310. Epub 2017 Dec 28.

引用本文的文献

1
Augmenting Treatment Arms With External Data Through Propensity-Score Weighted Power Priors: An Application in Expanded Access.通过倾向得分加权功率先验使用外部数据增强治疗组:在扩大准入中的应用
Stat Med. 2025 Aug;44(18-19):e70168. doi: 10.1002/sim.70168.
2
PS-SAM: propensity-score-integrated self-adapting mixture prior to dynamically and efficiently borrow information from historical data.PS-SAM:倾向得分整合自适应混合模型,用于动态高效地借鉴历史数据中的信息。
J Biopharm Stat. 2025 Apr 17:1-16. doi: 10.1080/10543406.2025.2489284.
3
Bayesian dynamic borrowing in group-sequential design for medical device studies.
医疗器械研究成组序贯设计中的贝叶斯动态借用法
BMC Med Res Methodol. 2025 Mar 20;25(1):78. doi: 10.1186/s12874-025-02520-6.
4
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial.药代动力学增强的贝叶斯借用方法用于儿科外推——以DINAMO试验为例
Ther Innov Regul Sci. 2025 Jan;59(1):112-123. doi: 10.1007/s43441-024-00707-5. Epub 2024 Oct 7.
5
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.基于多源可交换性建模的贝叶斯平台试验设计与混合对照。
Stat Med. 2024 May 30;43(12):2439-2451. doi: 10.1002/sim.10077. Epub 2024 Apr 9.
6
Bayesian sample size determination using commensurate priors to leverage pre-experimental data.使用相称先验来利用实验前数据的贝叶斯样本量确定。
Biometrics. 2022 Mar 6;79(2):669-683. doi: 10.1111/j.1541-0420.2005.00454.x.
7
Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes.基于药代动力学的贝叶斯借用方法增强以提高临床试验效率:恩格列净治疗 2 型糖尿病案例分析。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1386-1397. doi: 10.1002/psp4.13035. Epub 2023 Aug 30.
8
Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.使用二分类生存数据为贝叶斯无缝 II/III 期临床试验构建先验分布。
Stat Methods Med Res. 2023 May;32(5):963-977. doi: 10.1177/09622802231160554. Epub 2023 Mar 15.
9
Bayesian Statistics for Medical Devices: Progress Since 2010.贝叶斯统计学在医疗器械中的应用:2010 年以来的进展。
Ther Innov Regul Sci. 2023 May;57(3):453-463. doi: 10.1007/s43441-022-00495-w. Epub 2023 Mar 3.
10
Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors.在单参数模型的II期临床试验设计中使用信息量逐渐减少的先验分布时的早期终止。
Int J Clin Trials. 2022 Apr-Jun;9(2):107-117. doi: 10.18203/2349-3259.ijct20221110. Epub 2022 Apr 25.